Kintor shares plunge after hair-loss drug flops in clinical trials
The company’s drug has failed to show a significant hair-boosting effect in Phase III trials, dashing investors’ hopes for a ground-breaking treatment for baldness Key Takeaways: The disappointing test results…
FAST NEWS: Ascletis Pharma Soars after Expanding Production of Covid-19 Tablets
The latest: Ascletis Pharma Inc. (1672.HK) announced the expansion of its annual production capacity of ritonavir oral tablets, a component of oral direct-acting Covid-19 drug paxlovid, to 100 million tablets,…
FAST NEWS: Kintor Pharma Plunges after Covid-19 Drug Fails Clinical Trial
The latest: Kintor Pharmaceutical Ltd. (9939.HK) announced that an interim analysis of data from a multi-regional Phase III clinical trial for its oral drug proxalutamide to treat Covid-19 did not…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Yonghe Medical’s share repurchase gets results, but can’t hide a receding profit line
2279.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
FAST NEWS: Nomura takes up Kintor Pharma stake
9939.HK
- HighTide Therapeutics places big IPO bet on “affluenza” drug
